Current Colorectal Cancer Reports

, Volume 9, Issue 4, pp 391–397

Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer

  • Sandip P. Patel
  • Takuya Osada
  • Koya Osada
  • Herbert Hurwitz
  • H. Kim Lyerly
  • Michael A. Morse
Immunotherapy of Malignancy (MA Morse, Section Editor)

DOI: 10.1007/s11888-013-0184-3

Cite this article as:
Patel, S.P., Osada, T., Osada, K. et al. Curr Colorectal Cancer Rep (2013) 9: 391. doi:10.1007/s11888-013-0184-3

Abstract

T cell infiltration of colorectal cancer is associated with improved clinical outcome, underlining the importance of the immune system in cancer control; however, immune checkpoints, including the inhibitory T cell molecules CTLA-4 and PD-1 that temper the native immune response, mitigating autoimmunity, are coopted by tumors to facilitate escape from immune surveillance. Blockade of CTLA-4 and PD-1 and its ligand PD-L1, expressed by many tumors, have shown impressive activity in melanoma, renal cell carcinoma, and lung cancer. Immune checkpoint inhibition has been less well studied in colorectal cancer, but preclinical and clinical investigations are in progress.

Keywords

Colorectal cancer Immune checkpoint CTLA-4 PD-1 PD-L1 mCRC Immunomodulation Vaccine Colon cancer Ipilimumab Tremelimumab Nivolumab Lambrolizumab 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sandip P. Patel
    • 1
  • Takuya Osada
    • 1
  • Koya Osada
    • 1
  • Herbert Hurwitz
    • 1
  • H. Kim Lyerly
    • 1
  • Michael A. Morse
    • 1
  1. 1.Department of Medicine, Division of Medical OncologyDuke University Medical CenterDurhamUSA

Personalised recommendations